A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 427 participants.
Also called NCT01076075
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 427 participants
- Sponsor
- Registry
-
NCT01076075
-
- Other papers using this trial's data
- A randomized clinical trial evaluating the safety and efficacy of sitagliptin added to the combination of sulfonylurea and metformin in patients with type 2 diabetes mellitus and inadequate glycemic control
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Not reported
- Registry status
- Completed
Technical summary
Registry record NCT01076075. Randomized; double masking; primary purpose treatment. Start 2010-06-03 (actual); primary completion 2011-07-11 (actual). Results posted on 2012-08-07.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Sitagliptin phosphate
- Intervention (Drug)
- Comparator: placebo to pioglitazone
- Intervention (Drug)
- Comparator: placebo to Sitagliptin
- Intervention (Drug)
- Comparator: pioglitazone
- Intervention (Drug)
- Glimepiride or gliclazide
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- Pioglitazone rescue therapy
- Lead sponsor
- Merck Sharp & Dohme LLC
Record details
- Record id
cardio:ct-nct01076075- Content hash
dfcafdf7a45a8a5f2759608e64bcbb2fdd7cb287a41fe78b4754bc5fad53c119